iCardiac Technologies is an innovative, research-driven service provider for pharmaceutical cardiac safety trials. iCardiac develops and markets novel advanced ECG-based biomarkers, as well as improved methods for measuring standard ECG-based biomarkers in clinical trials. In addition, iCardiac offers a broad range of clinical trial services for acquisition, analysis, regulatory compliance and quality control of ECG data in clinical trials.
The benefits of iCardiac’s services offerings include:
Gaining not-elsewhere-available insight into the cardiac safety profiles (e.g., torsadogenic potential) of in-development compounds or on-market drugs.
Greatly reducing the number of “false positives” and “false negatives” when testing for cardiac safety.
Complying with the FDA E14 QT/QTc guidance for the industry.
“Best practice recommendations on utilizing advanced ECG Biomarkers in cardiac safety assessment of drugs in development”
iCardiac Technologies is the Recipient of Frost & Sullivan North American Cardiac Safety Analytics Technology Innovation of the Year Award.
Former Pfizer Research Fellow Assumes Key Role at iCardiac Technologies
iCardiac Announces Development of Next Generation COMPAS 3.0 Software Platform
iCardiac Technologies Raises Funds To Develop Personalized Approach to Cardiac Safety
Network Formed to Tackle Cardiac Safety Challenge
iCardiac Appoints Chief Financial Officer
iCardiac Appoints Three New Members to the Board of Directors
iCardiac Technologies Enters into Cardiac Safety Alliance with Pfizer
iCardiac Wins Technology Innovation Of The Year Award
iCardiac Technologies Completes Oversubscribed Series A Round
iCardiac Moves Into New Corporate Headquarters
Trillium Group And New York State Comptroller Announce Multi-Million Dollar Investment in iCardiac
Venture Capital Forum Selects Company for Best Presentation Award
iCardiac, URMC Ink Exclusive Agreement for Breakthrough Medical Technology
iCardiac Technologies Appoints Alex Zapesochny as President and COO
Screen Door is Wide Open as seen in R&D Directions April 2008
Universities and the local economy
True to Heart: ECG biomarkers are discussed in April 2008 online edition of Drug Discovery & Development
Strong pulse at iCardiac in Brighton
Integrated approach to TQT
CenterWatch Profile on Cardiac Safety Network
News 13 WHAM: "UR Spins Off Support for High Tech Business"
Engineering K12 Center: "Ending Pharmaceutical Heartbreak"
Rochester Medicine: “Leadership in Technology Commercialization”
Health Business Blog: "Interview with Chairman and CEO of iCardiac, Mike Totterman"
Rnews: "Entrepreneurs Make Their Pitch"
Start-Up Magazine (In Vivo Publication): "iCardiac Technologies Inc. - A Better Rhythm for Drug Development"
R&D Directions: "A Cardiac Pact"
QT and Arrhythmia Issues in Drug Development, April 6-8, 2008 at the Hyatt Regency Bethesda in Bethesda, MD.
October 15-31, 2007, hosted over the Internet by the International Society for Holter and Noninvasive Electrocardiology (ISHNE).
October 2nd, 2007 Durham, North Carolina
October 24th and 25th, 2007 Copthorne Tara Hotel, London
December 3-4, 2007, Dorint Praha Don Giovanni Hotel, Prague, Czech Republic
